A recent study evaluated 89Zr-anti-EGFR tumor uptake in 10 patients with wildtype K-RAS colorectal cancer and 89Zr-anti-HER3 uptake in 5 HER3-positive solid tumors [71]. This evidence concerns the gene ERBB3 and neoplasm.